Cargando…

PB1850: A DOSE FINDING AND EXPANSION OPEN LABEL, MULTICENTER STUDY OF IADADEMSTAT AND GILTERITINIB IN PATIENTS WITH RELAPSE/REFRACTORY ACUTE MYELOID LEUKEMIA WITH MUTATED FLT3: THE FRIDA STUDY

Detalles Bibliográficos
Autores principales:	Fathi, A., Molero, A., Gutierrez, S., Arévalo, M., Yang, H., Buesa, C., Limon, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430636/ http://dx.doi.org/10.1097/01.HS9.0000850252.38175.2e

Ejemplares similares

PB1897: GILTERITINIB IN TURKEY: EARLY ACCESS PROGRAM RESULTS
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2023)

PB1850: MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION COMBINED WITH CLAG REGIMEN IN REFRACTORY AND RELAPSED ACUTE MYELOID LEUKEMIA (NON-M3)
por: Wan, Kai, et al.
Publicado: (2023)

Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
por: Chew, Serena, et al.
Publicado: (2020)

Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia
por: Marjoncu, Dennis, et al.
Publicado: (2020)

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
por: Daver, Naval, et al.
Publicado: (2022)

Cost-effectiveness of gilteritinib for relapsed/refractory FLT3(mut+) acute myeloid leukemia
por: Pandya, Bhavik J, et al.
Publicado: (2021)

PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML
por: Patel, Anand, et al.
Publicado: (2023)

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
por: Hosono, Naoko, et al.
Publicado: (2021)

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION
por: Valdes, Cesar Rodriguez, et al.
Publicado: (2023)

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
por: Smith, Catherine C., et al.
Publicado: (2022)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
por: Kallel, F., et al.
Publicado: (2022)

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia
por: Salamero, Olga, et al.
Publicado: (2020)

PB1865: NPM1-MUT MONITORING DURING GILTERITINIB TREATMENT IDENTIFIES DIFFERENT DYNAMICAL PATTERNS IN RESPONSIVE PATIENTS
por: Sartor, Chiara, et al.
Publicado: (2023)

PB2262: PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKINN LYMPHOMA
por: Zahra, Kmira, et al.
Publicado: (2023)

PB2183: RELAPSE PREDICTS POOR OUTCOMES IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA POST ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Gavriilaki, E., et al.
Publicado: (2022)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan
por: Sugamori, Haruko, et al.
Publicado: (2022)

PB2606: REAL-WORLD EXPERIENCE OF HETROMBOPAG IN RELAPSE AND REFRACTORY IMMUNE THROMBOCYTOPENIA
por: Feng, Yimei, et al.
Publicado: (2023)

PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Kumar, Shaji, et al.
Publicado: (2023)

PB1887: NETWORK META-ANALYSIS OF PROGRESSION FREE SURVIVAL IN THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
por: Chanan-Khan, A., et al.
Publicado: (2022)

PB2063: CHARACTERISTICS AND THERAPEUTIC RESULTS OF PATIENTS WITH REFRACTORY/RELAPSED HODGKIN LYMPHOMA IN A TUNISIAN CENTER
por: Kammoun, F., et al.
Publicado: (2022)

PB2012: A PHASE 2 MULTIARM STUDY OF MAGROLIMAB COMBINATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Paul, B., et al.
Publicado: (2022)

PB2263: TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA.
por: Zahra, Kmira, et al.
Publicado: (2023)

PB2634: USE OF N-ACETYLCYSTEINE THERAPY IN PATIENTS WITH RELAPSED REFRACTORY THROMBOTIC THROMBOCYTOPENIC PURPURA
por: Beyler, Ozlem, et al.
Publicado: (2023)

PB1879: OVERALL SURVIVAL OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB IN ALBANIA (2018-2022)
por: Calliku, E., et al.
Publicado: (2022)

PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Krishnan, A., et al.
Publicado: (2022)

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia
por: Altman, Jessica K., et al.
Publicado: (2020)

PB2113: TREATMENT REFRACTORINESS AND RESPONSE RATES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA
por: Majd, Zahra, et al.
Publicado: (2023)

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
por: Perl, Alexander E., et al.
Publicado: (2022)

PB1965: INSIGHTS INTO RELAPSED AND REFRACTORY CHRONIC MYELOID LEUKEMIA: MOLECULAR-GENETIC, BIOCHEMICAL AND PROGNOSIS PATTERNS
por: Musteata, Vasile
Publicado: (2023)

PB2297: PHASE II STUDY OF BORTEZOMIB, CYTARABINE, AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
por: Shin, Junghoon, et al.
Publicado: (2023)

PB2164: EFFICACY AND SAFETY EVALUATION OF IXAZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IN THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: LI, Wen, et al.
Publicado: (2023)

PB2254: TREATMENT OUTCOME AND PROGNOSTIC FACTORS IN CHILDREN AND ADOLESCENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Ali, Nesreen, et al.
Publicado: (2023)

PB2093: OVERALL SURVIVAL IN RELAPSED-REFRACTORY MYELOMA PATIENTS DEPENDS ON CIRCULATING PLASMA CELLS QUANTITATION
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

PB1848: IN VITRO CHEMOSENSITIVITY ASSAY PREDICTS TREATMENT RESPONSE IN RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA
por: Cao, Yigeng, et al.
Publicado: (2023)

PB1847: A PHASE 1 STUDY TO INVESTIGATE CLN-049, A FLT3/CD3 BISPECIFIC T CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)
por: Abdul-Hay, Maher, et al.
Publicado: (2023)

PB1858: PROGNOSIS AND TREATMENT OF FLT3 MUTATED MYELOID SARCOMA IN THE ERA OF FLT3 INHIBITORS: RETROSPECTIVE EVALUATION IN 5 ITALIAN CENTERS.
por: Lessi, Federica, et al.
Publicado: (2023)

PB2010: RETROSPECTIVE STUDY OF RELAPSED/REFRACTORY MYELOMA PATIENTS FROM AN INDIAN TERTIARY CENTRE: RESPONSE MATTERS!!
por: Lavu, R. R., et al.
Publicado: (2022)

PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE
por: Hultcrantz, Malin, et al.
Publicado: (2023)

PB2259: THE NEW PD-1 INHIBITOR PROLGOLIMAB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN’S LYMPHOMA
por: Semenova, Anastasia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sam9cd6proov7kt0eb769cjb3r